首页> 美国卫生研究院文献>British Journal of Cancer >High dose rate brachytherapy before external beam irradiation in inoperable oesophageal cancer.
【2h】

High dose rate brachytherapy before external beam irradiation in inoperable oesophageal cancer.

机译:不能手术的食管癌外照射前高剂量率近距离放射治疗。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

To induce fast relief of dysphagia in patients with oesophageal cancer high dose rate (HDR) brachytherapy was applied before external radiotherapy in a prospective study. Seventy-four patients with inoperable oesophageal cancer (36 squamous cell, 38 adenocarcinoma) were treated with a combination of 10 Gy HDR brachytherapy, followed by 40 Gy in 4 weeks external beam radiotherapy (EBRT), starting 2 weeks later. Tumour response, as measured by endoscopy and/or barium swallow, revealed complete remission in 21 and partial response in 38 patients (overall response rate 80%). Improvement of dysphagia was induced by brachytherapy within a few days in 39%, and achieved at the end of treatment in 70% of patients. Further weight loss was prevented in 39 of the 59 patients who presented with weight loss. Pain at presentation improved in 12 out of 25 patients. Median survival was 9 months. No differences in either response rate or survival were found in squamous cell or adenocarcinoma. Side-effects were either acute with minimal discomfort in 32 (42%) or late with painful ulceration in five patients (7%), occurring after a median of 4 months. A fistula developed in six patients, all with concurrent tumour. In conclusion, brachytherapy before EBRT was a safe and effective procedure to induce rapid relief of dysphagia, especially when combined with EBRT.
机译:为了在食管癌患者中快速缓解吞咽困难,在一项前瞻性研究中应用高剂量率(HDR)近距离放射治疗。 74例无法手术的食道癌患者(36鳞状细胞癌,38腺癌)接受了10 Gy HDR近距离放射疗法的联合治疗,随后在4周内进行了40 Gy的外部束放射疗法(EBRT),开始于2周后。通过内窥镜检查和/或吞咽钡剂测量的肿瘤缓解显示21例完全缓解,38例部分缓解(总体缓解率为80%)。通过近距离放射治疗可以在几天内改善吞咽困难,其中有39%的患者在治疗结束后获得了改善。 59例出现体重减轻的患者中有39例阻止了进一步的体重减轻。 25例患者中有12例在陈述时疼痛得到改善。中位生存期为9个月。鳞状细胞癌或腺癌的反应率或生存率均无差异。不良反应为急性,有32例(42%)的轻微不适,或5例(7%)的疼痛性溃疡晚期,发生在中位数4个月后。 6名患者同时发生肿瘤而形成了瘘管。总之,EBRT之前的近距离放射疗法是一种快速有效的吞咽困难缓解方法,尤其是与EBRT结合使用时,是一种安全有效的方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号